In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $2.00. The company's shares closed last Thursday at $0.85, close to its 52-week low of $0.53. According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.2% and a 37.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $2.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-proqrs-stock-is-going-to-recover-4?utm_source=advfn.com&utm_medium=referral
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.